LINC01563: A Potential Drug Target and Biomarker (G101060544)

Target Name: LINC01563

NCBI ID: G101060544

LINC01563

Other Name(s): long intergenic non-protein coding RNA 1563 | Long intergenic non-protein coding RNA 1563, transcript variant 1 | HP08942

LINC01563: A Potential Drug Target and Biomarker

LINC01563 is a gene that has been identified as a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The gene is located on chromosome 18 and encodes a protein known as LINC01563, which is involved in several cellular processes, including cell adhesion, migration, and survival.

LINC01563 has been shown to be aberrantly expressed in several types of cancer, including breast, ovarian, and colorectal cancer. Studies have also shown that LINC01563 is involved in the development and progression of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Additionally, LINC01563 has been implicated in several autoimmune disorders, including rheumatoid arthritis and multiple sclerosis.

Given the potential involvement of LINC01563 in these diseases, researchers have been interested in investigating its potential as a drug target. One approach that has been explored is the use of small molecules, such as drugs that can modulate the activity of LINC01563, to treat these diseases.

One of the most promising small molecules that has been shown to interact with LINC01563 is called R1-843. R1-843 is a compound that was identified as a potential drug against neurodegenerative diseases, including Alzheimer's disease. Studies have shown that R1-843 can inhibit the activity of LINC01563 and protect against neurodegeneration in animal models of Alzheimer's disease.

Another small molecule that has been shown to interact with LINC01563 is called JSQ-2662. JSQ-2662 is a compound that is being investigated as a potential treatment for multiple sclerosis. Studies have shown that JSQ-2662 can modulate the activity of LINC01563 and reduce inflammation in animal models of multiple sclerosis.

While the use of small molecules like R1-843 and JSQ-2662 as potential drugs against LINC01563 and its associated diseases is still in its early stages, it holds great promise. With further research, these small molecules may become valuable tools for the treatment of a variety of diseases.

Protein Name: Long Intergenic Non-protein Coding RNA 1563

The "LINC01563 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01563 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets